Eli Lilly and Hims & Hers announced an agreement on Nov. 6 to make Lilly’s FDA-approved obesity medicines Zepbound and Foundayo available directly through Hims & Hers.
Eligible patients can consult a licensed provider on Hims & Hers and, if prescribed treatment, order the medicine for home delivery without being redirected to LillyDirect. Prescribing remains subject to the provider’s clinical judgment.
Lilly says self-pay prices start at $149 per month for Foundayo and $299 per month for Zepbound, matching its other self-pay pricing.
Hims & Hers agreed not to offer compounded versions or knockoffs of Lilly’s obesity medicines. The deal follows the company’s shift toward offering branded, FDA-approved weight-loss drugs.
The arrangement removes a step for patients, but financial terms were not disclosed. Analysts have also noted that branded medicines can carry lower margins for Hims & Hers.
Sources:
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Eli Lilly Picks Hims & Hers to Sell Its Obesity Drugs, Days Before Hims Reports
Lilly to sell obesity drugs directly on Hims & Hers site
Lilly to sell obesity drugs directly on Hims & Hers site
Hims & Hers Rises 4% as Eli Lilly Deal Brings Zepbound to Its Platform: “A Clear Positive”
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
Eli Lilly Strikes Surprising Deal With Hims & Hers
Hims & Hers to Offer Eli Lilly's Weight-Loss Drugs
Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is ...
Lilly to sell obesity drugs directly on Hims & Hers site
Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity ...
Hims Surges On 'Surprising And Inevitable' Deal With Eli Lilly
Obesity telehealth deal adds Hims to Lilly's growing network of partners